Expert consensus statement on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: 2024 update.
СтатьяConsensus StatementКлинические рекомендацииНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nash Peter, Kerschbaumer Andreas, Konzett Victoria, Aletaha Daniel, Dörner Thomas, Fleischmann Roy, McInnes Iain, Primdahl Jette, Sattar Naveed, Tanaka Yoshiya, Trauner Michael, Winthrop Kevin, de Wit Maarten, Askling Johan, Baraliakos Xenofon, Boehncke Wolf-Henning, Emery Paul, Gossec Laure, Isaacs John D, Krauth Maria, Lee Eun Bong, Maksymowych Walter, Pope Janet, Scholte-Voshaar Marieke, Schreiber Karen, Schreiber Stefan, Stamm Tanja, Taylor Peter C, Takeuchi Tsutomu, Tam Lai-Shan, Van den Bosch Filip, Westhovens Rene, Zeitlinger Markus, Smolen Josef S
Аннотация
In light of the introduction of new Janus kinase inhibitors (JAKi), new indications for JAKi and recent safety considerations that have arisen since the preceding consensus statement on JAKi therapy, a multidisciplinary taskforce was assembled, encompassing patients, health care professionals, and clinicians with expertise in JAKi therapy across specialties. This taskforce, informed by two comprehensive systematic literature reviews, undertook the objective to update the previous expert consensus for using JAKi developed in 2019. The taskforce deliberated on overarching principles, indications, dosage and comedication strategies, warnings and contraindications, screening protocols, monitoring recommendations, and adverse effect profiles. The methodology was based on the European Alliance of Associations for Rheumatology standard operating procedures, with voting on these important elements. Furthermore, an updated research agenda was proposed. The task force did not address when a JAKi should be prescribed but rather considerations once this decision has been made. This update aimed to equip clinicians with the necessary knowledge and guidance for the efficient and safe administration of this expanding and significant class of drugs.